Login to Your Account



Edinburgh BioQuarter, GSK Partner for Pancreatitis R&D

By Nuala Moran
BioWorld International Correspondent

Wednesday, October 26, 2011

LONDON – The new Edinburgh BioQuarter made the first step toward its aim of becoming Scotland's translational research hub, signing a drug discovery collaboration with GlaxoSmithKline plc in acute pancreatitis.

The deal follows a trawl by GSK as it hunts for 10 projects for its recently established university collaboration scheme, the Academic Discovery Performance Unit.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription